by Juliette Boynton | Nov 1, 2018 | Briefings, UK
Warner-Lambert originally developed its compound pregabalin, which it sold under the mark Lyrica, as an anti-convulsant, anti-anxiety, anti-psychotic medication, in particular for the treatment of epilepsy and generalised anxiety disorder. It obtained patent...
by Juliette Boynton | Nov 1, 2018 | Briefings, US & International
Following the UK Supreme Court decision in Actavis v Eli Lilly in which Lord Neuberger concluded that the term “sodium” also covered “potassium” as an equivalent, a judgement was handed down in Milan also concerning the scope of protection of...
by Juliette Boynton | Oct 1, 2018 | Briefings, UK
Gilead was the owner of an SPC for a combination of two actives, namely tenofovir and emtricitabine, which they market as Truvada®, which Teva and others wished to revoke. Interestingly, Gilead also sells tenofovir alone in the absence of an SPC. In accordance with...
by Dr Andrew Clements | Jun 1, 2018 | Briefings, UK
Introduction SPCs are national rights provided for by EU regulations. The European Commission published a proposal for a new Regulation on 28 May 2018 to amend Regulation (EC) No469/2009 concerning the SPC for medicinal products. Further details of the proposal can be...
by David Eyre | Mar 1, 2018 | Briefings, US & International
Extending the patent term for such high value patented products can be particularly significant for rights holders even when the additional term is mere days. A supplementary protection certificate is intended to partially compensate a patent holder for the patent...
Recent Comments